On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure
<p>Abstract</p> <p>Background</p> <p>Trials of iron chelator regimens have increased the treatment options for cardiac siderosis in beta-thalassemia major (TM) patients. Treatment effects with improved left ventricular (LV) ejection fraction (EF) have been observed in p...
Main Authors: | Carpenter JP, Pennell DJ, Roughton M, Cabantchik ZI |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-09-01
|
Series: | Journal of Cardiovascular Magnetic Resonance |
Online Access: | http://www.jcmr-online.com/content/13/1/45 |
Similar Items
-
Role of iron carboxymaltose therapy in heart failure with reduced ejection fraction
by: V.K. Katyal, et al.
Published: (2017-11-01) -
Thalassemia Major: Transplantation or Transfusion and Chelation
by: Said Y. Mohamed
Published: (2017-12-01) -
IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES
by: Paolo Cianciulli
Published: (2009-06-01) -
Renal Function in Children with β-Thalassemia Major Treated with Iron Chelating Agent
by: Olga Rasiyanti Siregar, et al.
Published: (2020-09-01) -
The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Mohammad Ali Mashhadi, et al.
Published: (2011-06-01)